Search research articles
Contact Us
Filters
Showing results (631-640 of 652) with videos related to
Page
of 66
Sort By:
Journal of Hematology & Oncology
|
April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Maria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
The Lancet. Haematology
|
June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Blood Advances
|
February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Blood
|
December 17, 2025
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs
Tomas Jelinek, David Žihala, Aintzane Zabaleta, et al.
American Journal of Hematology
|
June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
The New England Journal of Medicine
|
December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
Hemasphere
|
November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
The Lancet. Oncology
|
July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vania Hungria, Paweł Robak, Marek Hus, et al.
Blood
|
November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Page
of 66
Search research articles
Search
Showing results (631-640 of 652) with videos related to
Sort By:
Page
of 66
Journal of Hematology & Oncology
|
April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Maria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
The Lancet. Haematology
|
June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Blood Advances
|
February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Blood
|
December 17, 2025
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs
Tomas Jelinek, David Žihala, Aintzane Zabaleta, et al.
American Journal of Hematology
|
June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
The New England Journal of Medicine
|
December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
Hemasphere
|
November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
The Lancet. Oncology
|
July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vania Hungria, Paweł Robak, Marek Hus, et al.
Blood
|
November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Page
of 66